Drugs in Context’s Post

The emerging landscape of targeted therapies, particularly biologics and small molecule agents, offers new hope by providing more effective and tailored treatment options. However, the integration of personalized treatment strategies, and patient-centered care remains crucial for optimizing outcomes and enhancing the quality of life for psoriasis patients. This podcast will discuss these key issues and explore the potential of innovative therapies in improving patient outcomes. Follow the link in our bio for FREE AMA, ABS, ANCC or ACPE credit! #psoriasis #dermatology #practicepointcme #freecme

Discover G-Med's latest insights on psoriasis treatment! Our new report dives into key concerns like treatment resistance, long-term management, and regional differences in care. Learn how global experts are addressing challenges with biologics, quality of life, and patient follow-up. Don’t miss out on these valuable perspectives- Link to the full report below! #PsoriasisCare #BiologicTherapies #Dermatology #Rheumatology #HealthcareInsights SUN PHARMA Janssen Inc. Novartis Amgen AbbVie

Dr Ashley O'Toole and Dr Melinda Gooderham in Vienna, Austria 🇦🇹 with a group of Canadian delegates to discuss atopic dermatitis, prurigo nodularis and Type 2 inflammation with global colleagues. 👍 This was an excellent opportunity for them to brush up on their presentation skills and exchange insights and their clinical trial experience with dupilumab with international experts in the field. #dermatology #globalcollaboration #Type2inflammation #atopicdermatitis #prurigonodularis

New article in Drugs in Context Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature Anna Paola Lugli, Giacomo Caldarola, Gianmarco Falco, Costanza Montedoro, Camilla Mulas, Clara De Simone Article describing two cases of new-onset bullous pemphigoid in patients treated with anti-IL-17 drugs for psoriasis. #drugsincontext #dermatology #mabs #IL17 #treatment #pharmacology https://lnkd.in/dqenggh3

Eli Lilly and Company announced that the FDA has approved EBGLYSS™ (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis (eczema) in patients 12 years and older who are not well-controlled with topical therapies.    The approval is based on the ADvocate and ADhere studies, offering a new treatment option for those with hard-to-control eczema symptoms. EBGLYSS reduces inflammation and symptoms like dry, itchy skin. Clinical trials showed 38% of patients achieved clearer skin by Week 16, with many experiencing itch relief as early as two weeks.    Read more: https://lnkd.in/eEbQXZFD   #Dermatology #AtopicDermatitis #Eczema

💡 CLINICAL PEARLS: Dive into the evolving world of systemic therapies for atopic dermatitis! 🌟 From traditional immunosuppressants to modern biologics and JAK inhibitors, discover how personalized care is shaping treatment decisions. 🎤 Featuring Dr Joy Wan, Assistant Professor of Dermatology at Johns Hopkins. https://okt.to/8XeGdz #AtopicDermatitis #Dermatology #SystemicTherapies #Biologics #JAKInhibitors #ChronicSkinConditions #PersonalizedCare #MedicalInnovation #APPInstituteDermatology

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with moderate-to-severe prurigo nodularis (PN), has achieved both primary and all key secondary goals. GALDERMA R&D global head Baldo Scassellati Sforzolini said: “These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent US Food and Drug Administration approval for the treatment of adults with PN" Click here for the full article - https://lnkd.in/dCT3sRJx #clinicaltrials #dermatology

🔍 Join PPD for an upcoming webinar on the essential role of scientific surveillance in ensuring data integrity in dermatology clinical trials! Learn how advanced statistical monitoring techniques can identify risks and inconsistencies to enhance trial outcomes. 💡 This session will explore the unique challenges of dermatology trials, including the impact of topical treatments and the importance of a quality-by-design approach. Discover how scientific surveillance can safeguard data quality and prevent aberrations across all clinical research areas. ➡️ REGISTER HERE: https://buff.ly/40j0pDC #Dermatology #ClinicalTrials #DataIntegrity #ScientificSurveillance #Healthcare #Research #Pharmaceuticals #DataQuality #Innovation

🚨 New data at #FallClinical: Lebrikizumab-lbkz (Ebyglyss) treatment of moderate-to-severe #AtopicDermatitis led to improvements in patients’ skin (including hands and face) and itch among those who were previously treated with dupilumab. These findings were announced by Elil Lilly & Company and authored by such investigators as Linda Stein Gold, MD, of Henry Ford Health. To learn more, check out our summary here: https://lnkd.in/g6dnUyCF #dermatology #lebrikizumab #eczema

Repurposing of known medications beyond their original therapeutic indications is an increasingly attractive drug development path. Offering a cost-effective and time-efficient approach, this strategy is not a challenge-free process: issues related to intellectual property, drug formulation barriers or funding need to be surpassed. Successfully facing these challenges, BioResearch Pharma SA aims to provide new treatment options for dermatology patients. The company pipeline features drug repurposed candidates for psoriasis and androgenetic alopecia. Effective topical dermatology treatments can improve the quality of life for many patients. #pharma #dermatology